A Phase 3 interventional study of ATX-101 and Placebo in Moderate to Severe Convexity of Submental Fat, Safety and Efficacy, sponsored by Kythera Biopharmaceuticals. Completed at 6 sites in United States. Open to participants aged 65 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-17.
Sponsored by Kythera Biopharmaceuticals (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objectives of this study are to explore the safety and efficacy of subcutaneous injections of Deoxycholic Acid relative to placebo, in the submental area of participants who are 65 to 75 years old.
Kythera Biopharmaceuticals is the lead sponsor of 23 studies on the registry; none are open to participants now.
First submitted before Kythera Biopharmaceuticals became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo administered in 0.2 mL subcutaneous (SC) injections, up to 10 milliliters (mL) per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
Drug: Placebo
Participants received deoxycholic acid 2 mg/cm\^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
Drug: ATX-101
Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
Also known as: deoxycholic acid
Phosphate buffered saline placebo for injection
Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments
The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).
Time frame: Baseline and up to Week 32 (12 weeks after last treatment)
Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments
The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).
Time frame: Baseline and up to Week 32 (12 weeks after last treatment)
Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)
The investigator evaluated the participant's chin and neck area using the CR-SMFRS 5-point scale where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst).
Time frame: Baseline and up to Week 32 (12 weeks after last treatment)
Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)
The investigator evaluated the participant's chin and neck area using the CR-SMFRS 5-point scale where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst).
Time frame: Baseline and up to Week 32 (12 weeks after last treatment)
Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Patient-Reported Submental Fat Rating Scale (PR-SMFRS)
The participant evaluated their chin and neck area using the PR-SMFRS 5-point scale where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).
Time frame: Baseline and up to Week 32 (12 weeks after last treatment)
Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Patient-Reported Submental Fat Rating Scale (PR-SMFRS)
The participant evaluated their chin and neck area using the PR-SMFRS 5-point scale where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).
Time frame: Baseline and up to Week 32 (12 weeks after last treatment)
Change From Baseline in Submental Skin Laxity Grade Scale (SMSLG)
The SMSLG is an integration of three features: skin wrinkling, adherence to underlying neck structures (bone and muscle) and redundancy (horizontal and vertical folds). Each grade (1=none, 2=mild, 3=moderate and 4=severe) defines the maximal allowed limit for skin wrinkling, adherence to underlying structures and redundancy.
Time frame: Baseline and up to Week 32 (12 weeks after last treatment)
A total of 55 subjects were randomized to either ATX-101 or placebo at a ratio of 1:1. A total of 28 subjects received ATX-101 and 26 subjects received placebo; 1 subject (803-003) was randomized to placebo but was not treated with placebo.
| Milestone | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Started | 28 | 27 |
| Completed | 25 | 24 |
| Not completed | 3 | 3 |
| Withdrew: Withdrawal of consent | 3 | 2 |
| Withdrew: Administrative decision | 0 | 1 |
The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).
| percentage of participants | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments | 68.0 (49.7 to 86.3) | 25.0 (7.7 to 42.3) |
The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).
| percentage of participants | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments | 8.0 (0.0 to 18.6) | 4.2 (0.0 to 12.2) |
The investigator evaluated the participant's chin and neck area using the CR-SMFRS 5-point scale where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst).
| percentage of participants | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) | 84.0 (69.6 to 98.4) | 41.7 (21.9 to 61.4) |
The investigator evaluated the participant's chin and neck area using the CR-SMFRS 5-point scale where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst).
| percentage of participants | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) | 60.0 (40.8 to 79.2) | 12.5 (0.0 to 25.7) |
The participant evaluated their chin and neck area using the PR-SMFRS 5-point scale where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).
| percentage of participants | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Patient-Reported Submental Fat Rating Scale (PR-SMFRS) | 80.0 (64.3 to 95.7) | 45.8 (25.9 to 65.8) |
The participant evaluated their chin and neck area using the PR-SMFRS 5-point scale where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).
| percentage of participants | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Patient-Reported Submental Fat Rating Scale (PR-SMFRS) | 20.0 (4.3 to 35.7) | 20.8 (4.6 to 37.1) |
The SMSLG is an integration of three features: skin wrinkling, adherence to underlying neck structures (bone and muscle) and redundancy (horizontal and vertical folds). Each grade (1=none, 2=mild, 3=moderate and 4=severe) defines the maximal allowed limit for skin wrinkling, adherence to underlying structures and redundancy.
| scores on a scale | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Change From Baseline in Submental Skin Laxity Grade Scale (SMSLG) | -0.5 ± 0.65 | -0.1 ± 0.45 |
Collected over Up to 32 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ATX-101 (Deoxycholic Acid) Injection | 0/28 (0%) | 0/28 (0%) | 28/28 (100%) |
| Placebo | 0/26 (0%) | 1/26 (3.8%) | 23/26 (88.5%) |
| Event | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| UrosepsisInfections and infestations | 0/28 | 1/26 |
| Event | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Injection site bruisingGeneral disorders | 20/28 | 15/26 |
| Injection site painGeneral disorders | 20/28 | 3/26 |
| Injection site swellingGeneral disorders | 17/28 | 15/26 |
| Injection site anaesthesiaGeneral disorders | 14/28 | 0/26 |
| Injection site noduleGeneral disorders | 8/28 | 3/26 |
| Injection site oedemaGeneral disorders | 5/28 | 0/26 |
| Injection site erythemaGeneral disorders | 4/28 | 3/26 |
| Injection site indurationGeneral disorders | 4/28 | 0/26 |
| NasopharyngitisInfections and infestations | 0/28 | 2/26 |
| HeadacheNervous system disorders | 1/28 | 2/26 |
| Age, Continuous(years) | ATX-101 (Deoxycholic Acid) Injection | Placebo | Total |
|---|---|---|---|
| Mean | 68.1 ± 2.76 | 67.7 ± 2.30 | 67.9 ± 2.53 |
| Age, Customized(Participants) | ATX-101 (Deoxycholic Acid) Injection | Placebo | Total |
|---|---|---|---|
| 65-69 years | 22 | 22 | 44 |
| 70-75 years | 6 | 5 | 11 |
| Sex: Female, Male(Participants) | ATX-101 (Deoxycholic Acid) Injection | Placebo | Total |
|---|---|---|---|
| Female | 23 | 21 | 44 |
| Male | 5 | 6 | 11 |
| Ethnicity (NIH/OMB)(Participants) | ATX-101 (Deoxycholic Acid) Injection | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 27 | 25 | 52 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | ATX-101 (Deoxycholic Acid) Injection | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 4 |
| White | 25 | 25 | 50 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Fitzpatrick Skin Type(Participants) | ATX-101 (Deoxycholic Acid) Injection | Placebo | Total |
|---|---|---|---|
| I | 0 | 1 | 1 |
| II | 15 | 10 | 25 |
| III | 7 | 12 | 19 |
| IV | 2 | 1 | 3 |
| V | 3 | 2 | 5 |
| VI | 1 | 1 | 2 |
| Weight(kg) | ATX-101 (Deoxycholic Acid) Injection | Placebo | Total |
|---|---|---|---|
| Mean | 77.44 ± 14.170 | 84.10 ± 14.070 | 80.71 ± 14.388 |
| Body Mass Index (BMI)(kg/m^2) | ATX-101 (Deoxycholic Acid) Injection | Placebo | Total |
|---|---|---|---|
| Mean | 29.27 ± 4.207 | 30.72 ± 4.694 | 29.98 ± 4.471 |
4 further baseline measures are reported on the registry.
The record gives a start of Apr 2014, a primary completion of Aug 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2020, 4 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: APIM-containing Peptide ATX-101